Europska Unija - engleski - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nintedanib - idiopathic pulmonary fibrosis - antineoplastic agents - ofev is indicated in adults for the treatment of idiopathic pulmonary fibrosis (ipf).

Europska Unija - engleski - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nintedanib - carcinoma, non-small-cell lung - antineoplastic agents - vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (nsclc) of adenocarcinoma tumour histology after first line chemotherapy.

Europska Unija - engleski - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin, linagliptin - diabetes mellitus, type 2 - drugs used in diabetes - glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (su) and one of the monocomponents of glyxambi do not provide adequate glycaemic control;when already being treated with the free combination of empagliflozin and linagliptin.

Europska Unija - engleski - EMA (European Medicines Agency)

boehringer ingelheim - empagliflozin, metformin - diabetes mellitus, type 2 - drugs used in diabetes - synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients inadequately controlled on their maximally tolerated dose of metformin alone;in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;in patients already being treated with the combination of empagliflozin and metformin as separate tablets.

Europska Unija - engleski - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin - diabetes mellitus, type 2 - drugs used in diabetes - trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:as monotherapyin patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.as combination therapyin combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Europska Unija - engleski - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - dabigatran etexilate mesilate - arthroplasty, replacement; venous thromboembolism - antithrombotic agents - pradaxa 75 mgprimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.pradaxa 110 mgprimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischemic attack (tia); age ≥ 75 years; heart failure (nyha class ≥ ii); diabetes mellitus; hypertension.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.pradaxa 150 mgprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischemic attack (tia); age ≥ 75 years; heart failure (nyha class ≥ ii); diabetes mellitus; hypertension.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

Malta - engleski - Malta Medicines Authority

boehringer ingelheim international gmbh binger strasse 173, 55216 ingelheim am rhein, germany - alteplase - powder and solvent for solution for infusion or injection - alteplase 10 mg - antithrombotic agents

Singapur - engleski - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - fenoterol hydrobromide; ipratropium bromide monohydrate 0.52mg/4ml eqv. to ipratropium bromide anhydrous - solution - 1.25 mg/4 ml - fenoterol hydrobromide 1.25 mg/4 ml; ipratropium bromide monohydrate 0.52mg/4ml eqv. to ipratropium bromide anhydrous 0.5 mg/4 ml

Novi Zeland - engleski - Ministry for Primary Industries

boehringer ingelheim animal health new zealand limited - firocoxib - firocoxib 240 g/kg - analgesic

Irska - engleski - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - interferon gamma - solution for injection - international unit - interferons